beta-Endorphin in the median preoptic nucleus modulates the pressor response induced by subcutaneous hypertonic sodium chloride.
Considerable evidence has been gathered involving the endogenous opioid system in blood pressure regulation. In the present study, we investigated the effect of administering beta-Endorphin into the median preoptic nucleus (MnPO) on blood pressure (BP) and heart rate (HR) and whether this administration was capable of modulating the pressor response observed after an acute increase in plasma osmolality. In urethane-anaesthetized Wistar rats, different doses of beta-Endorphin (1, 10, 25 ng) were microinjected into the MnPO to elucidate a putative role for beta-Endorphin in BP and HR regulation. Additionally, we evaluated the modulatory effect of the beta-Endorphin injection (25 ng) into the MnPO on the pressor response to subcutaneous sodium chloride solution administration (2 M NaCl, 0.1 ml/10 gbw). The MnPO-beta-Endorphin microinjection resulted in a dose-dependent hypotensive and bradycardic effect and pre-treatment with the opioid antagonist, naloxone (100 ng), injected in the same nucleus, significantly antagonized the cardiovascular response to beta-Endorphin administration in the MnPO. On the other hand, a microinjection of beta-Endorphin (25 ng) into the median preoptic nucleus abolished the pressor response to a subcutaneous injection of hypertonic saline. It is concluded from these results that beta-Endorphin-MnPO administration produces a decrease in BP and HR in normotensive animals and also inhibits the pressor response evoked by an acute increase in plasma osmolality.
Caeiro
Ximena
X
Instituto de Investigación Médica Mercedes y Martín Ferreyra (INIMEC-CONICET), Córdoba, Argentina.
Vivas
Laura
L
D000704:Analysis of Variance; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006339:Heart Rate / Q000187:drug effects; D007279:Injections, Subcutaneous / Q000379:methods; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009994:Osmolar Concentration; D010949:Plasma / Q000187:drug effects; D011301:Preoptic Area / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D012462:Saline Solution, Hypertonic / Q000494:pharmacology*; D013997:Time Factors; D001615:beta-Endorphin / Q000494:pharmacology*
D009292:Narcotic Antagonists; D012462:Saline Solution, Hypertonic; D009270:Naloxone; D001615:beta-Endorphin